Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR-engineered T cells in patients with refractory cancer

6 Feb 2020

Abstract excerpt

CRISPR takes first steps in humans CRISPR-Cas9 is a revolutionary gene-editing technology that offers the potential to treat diseases such as cancer, but the effects of CRISPR in patients are currently unknown. Stadtmauer et al. report a phase 1 clinical trial to assess the safety and feasibility of CRISPR-Cas9 gene editing in three patients with advanced cancer (see the Perspective by Hamilton and Doudna). They...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Cytomegalovirus and herpesvirus research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32029687
DOI: 10.1126/science.aba7365

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR-engineered T cells in patients with refractory cancerPMID 32029687Read ↗

CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancerSemantic proximity Read ↗

CRISPR/Cas9: Role of genome editing in cancer immunotherapySemantic proximity Read ↗

CRISPR–Cas9 applications in T cells and adoptive T cell therapiesSemantic proximity Read ↗

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapySemantic proximity Read ↗

The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancerSemantic proximity Read ↗

Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapySemantic proximity Read ↗

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapySemantic proximity Read ↗

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerSemantic proximity Read ↗

Boosting CAR-T cell therapy with CRISPR technologySemantic proximity Read ↗

Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for CancerSemantic proximity Read ↗

CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell TherapySemantic proximity Read ↗

Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.